Navigation Links
AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
Date:6/4/2008

Wilmington, DE June 4, 2008 AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the long-term maintenance treatment of asthma in pediatric patients ages 6 to 11 years old. SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.

"Millions of children in the U.S. are affected by asthma1," said lead investigator Jeffrey Leflein, MD, Allergy & Immunology Associates of Ann Arbor, Michigan. "SYMBICORT could potentially offer another treatment option for the long-term maintenance of asthma in young children whose condition is not adequately controlled with inhaled corticosteroids alone."

The submission package is based on a robust clinical development program consisting of five active or placebo-controlled Phase III trials assessing the efficacy and safety of SYMBICORT pressurized metered-dose inhaler (pMDI) that included 1,446 children ages 6 to 11 years old with asthma.2 The proposed starting dose for children (80/9 mcg twice-daily) was studied in one pivotal randomized, double-blind, active-controlled, 12-week study that evaluated 256 children ages 6 to 11 years old with mild-to-moderate persistent asthma previously treated with inhaled corticosteroid therapy.3 In this study, SYMBICORT was compared to budesonide pMDI and formoterol dry powder inhaler.3 A second study evaluating this dose included 351 subjects ages 6 to 11 years old.4 Results from both studies demonstrated that SYMBICORT 80/9 mcg twice daily had a similar safety profile to one of the mono-components, budesonide;4,5 likewise, results from the first study also found that SYMBICORT 80/9 mcg twice daily had a similar safety profile to its other mono-component, formoterol.5 The most common adverse events reported wer
'/>"/>

Contact: Katie Neff
katie.neff@astrazeneca.com
302-885-9960
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
2. A Drug That Carries a Lower Risk of Weight Gain Than AstraZenecas Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment
3. Washington University in St. Louis and AstraZeneca Announce Alzheimers Research Collaboration
4. Solcara Helps AstraZeneca Set International Benchmark for Global Media Relations
5. AstraZeneca Gives $1.5 million to Support North Carolina Worksite Wellness Project
6. AstraZeneca - Biologics Day Interviews With Senior Management
7. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
8. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
11. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... March 06, 2015 Jvion, the ... release of a Clostridium Difficile (C Diff) predictive ... C Diff use case is the latest in ... hospital acquired infections, chronic conditions, and individual illnesses. ... C Diff solution flags at risk individuals to ...
(Date:3/6/2015)... 2015 Utilizing the latest in nutritional ... their ideal weight has enabled Diet Doc to add ... already impressive collection of fat loss enhancement medications. And ... promotions and savings to help people throughout the country ... promotion is especially appealing to new clients because they ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 The ... Canadian Celiac Association, is pleased to announce that ... Dufflet Rosenberg, has expanded their product line of ... are as scrumptious and as satisfying as any ... from scratch, and never contains hydrogenated fats or ...
(Date:3/6/2015)... Los Angeles cosmetic dentist , Dr. Poneh ... Zoom is a special type of teeth whitening treatment that ... whitening treatments, Zoom does its job in about an hour ... limited time, Dr. Ghasri is offering Zoom for just $195. ... $650 and allows patients to try out this revolutionary whitening ...
(Date:3/6/2015)... Fluid Running® Owner, Jennifer Conroyd, an Ironman ... Fluid Running® method 3 years ago when she ... hit upon the trifecta of combining matched-bpm music, the ... deep water running technique. She not only completed her ... workout that made the experience both enjoyable and a ...
Breaking Medicine News(10 mins):Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, is Now Offering a Promotion on Zoom Whitening 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3
... majority of Americans professing belief in God favor cooperative ... of nuclear weapons - branding it a moral obligation ... by the University of Maryland,s Center for International and ... International Policy Attitudes (PIPA). The nearly 1,500 Americans ...
... drugs are taken significantly extended the lives of women with ... the drugs anastrozole and fulvestrant in combination lived more than ... sequence, researchers reported Dec. 7 at the 2011 CTRC-AACR San ... standard of care for how we treat these patients," said ...
... recognize the following scenario: Their favorite player scores a three-point ... ball. But does the fact that he scored the last ... it change the probability that he will score again? ... Neiman at the Hebrew University in Jerusalem shatters the myth ...
... 15-minute walk can cut snacking on chocolate at work by ... study showed that, even in stressful situations, workers eat only ... short burst of physical activity. Published in the journal ... that short breaks away from their desks can help keen ...
... , WEDNESDAY, Dec. 7 (HealthDay News) -- Some ... research shows, but the findings do not suggest that this ... ventricle is one of the four chambers in the heart ... athletes in Australia who competed in one of four types ...
... "Up until now infarct size has only been measured as ... The reason being that the reference method of gadolinium based ... of time to perform, and can only be undertaken by ... University of Padua, Italy. "The advantages of STE over MRI ...
Cached Medicine News:Health News:US believers favor international action on climate change, nuclear risk: UMD poll 2Health News:US believers favor international action on climate change, nuclear risk: UMD poll 3Health News:Changing order drugs are taken boosts breast cancer survival 2Health News:Heads up Kobe Bryant! Research shows that trying for another 3-pointer is a mistake 2Health News:Short walk cuts chocolate consumption in half 2Health News:Marathons May Damage Part of Heart: Study 2Health News:Echocardiography offers the future for infarct size quantification 2Health News:Echocardiography offers the future for infarct size quantification 3Health News:Echocardiography offers the future for infarct size quantification 4
(Date:3/5/2015)... Corporation (Nasdaq: IRIX ) today reported financial results ... , Revenues were $11.8 million in the fourth ... 11% from $10.6 million in the 2013 fourth quarter. Revenues ... from $38.3 million in 2013. , Gross margin for ... the fourth quarter of the prior year. , Operating ...
(Date:3/5/2015)... March 5, 2015  BioPhotas, Inc., an FDA registered ... patented photo-therapeutic technologies to treat skin, muscle and joint ... Semper Fi Fund to provide BioPhotas, flagship product, the ... pain management solutions.  Commenting on the ... who used the Celluma at the Warrior Hope and ...
(Date:3/5/2015)... 5, 2015   ndd Medical Technologies , a ... employs precise ultrasound technology, announced that its EasyOne Pro® ... the San Antonio Pulmonary Fibrosis Support Group. The clinic ... fibrosis (PF), as well as those suspected of having ... a mere 12 square inches, EasyOne Pro provides accurate ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... Aethlon Medical, Inc. (OTC Bulletin Board: ... filtration devices to address infectious disease and cancer, ... entitled: " A Platform to Address Bioterrorism." ... at: http://www.aethlonmedical.com/knowledge-center/special-reports/ ...
... 2010 Northwestern Memorial Hospital is one ... will test whether operable lung cancer patients and their ... by hardwiring data systems to reduce medical error and ... trial co-sponsored by the Commission on Cancer and the ...
Cached Medicine Technology:'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 2'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 3'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 4Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 2Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: